PACB Stock Recent News

MENLO PARK, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter ended March 31, 2025.

Collaboration leverages HiFi's unique ability to reveal hidden variants, bringing a new level of precision to early life genetic screening Collaboration leverages HiFi's unique ability to reveal hidden variants, bringing a new level of precision to early life genetic screening

In the latest trading session, Pacific Biosciences of California (PACB) closed at $1.11, marking a -1.77% move from the previous day.

Company licenses novel deep learning-based epigenetic models from CUHK enabling the detection of 5hmC, 5mC hemimethylation, and 6mA in standard sequencing runs Company licenses novel deep learning-based epigenetic models from CUHK enabling the detection of 5hmC, 5mC hemimethylation, and 6mA in standard sequencing runs

In the latest trading session, Pacific Biosciences of California (PACB) closed at $1.17, marking no change from the previous day.

International research team aims to develop better understanding of Alzheimer's disease and dementia in diverse populations International research team aims to develop better understanding of Alzheimer's disease and dementia in diverse populations

Implements Plan to Reduce Annualized Operating Expense Run Rate by $45 Million to $50 Million Q1 2025 Earnings Conference Call Scheduled for May 8, 2025 MENLO PARK, Calif., April 09, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced preliminary, unaudited revenue for the quarter ended March 31, 2025.

MENLO PARK, Calif., April 04, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading provider of high-quality, highly accurate sequencing platforms, today announced that the Compensation Committee of the Company's Board of Directors granted a non-qualified stock option (the “Option”) covering 342,432 shares of PacBio common stock to the Company's recently hired Chief Financial Officer, Jim Gibson, under the Pacific Biosciences 2020 Inducement Equity Incentive Plan (the “2020 Inducement Plan”), effective on March 31, 2025. The award was granted as an inducement material to such individual's entering into employment with PacBio in accordance with Nasdaq Marketplace Rule 5635(c)(4).

Pacific Biosciences of California has hired Jim Gibson as its new chief financial officer, effective March 31.

MENLO PARK, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- PacBio  (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced Jim Gibson will join and be appointed as the company's new Chief Financial Officer, effective as of his start date, which is expected to be March 31, 2025. With over three decades of financial leadership experience at some of Silicon Valley's most iconic and innovative companies, Mr. Gibson brings a deep track record of operational excellence, strategic financing, and scaling global organizations.